{"entity":{"id":"nct07007767","kind":"trial","name":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","aka":[],"tldr":"A phase 2 trial of sintilimab, bevacizumab and decitabine in colorectal cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, not yet recruiting.","summary":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies） is a phase 2, interventional study registered as NCT07007767 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 32 participants, started 2025-06-15 and due to reach its primary completion in 2026-12-30. Interventions recorded: sintilimab; Bevacizumab Biosimilar; Decitabine. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator Assessment. Colorectal eligibility wording from the registry: \"Histologically confirmed colorectal adenocarcinoma;\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07007767","url":"https://clinicaltrials.gov/study/NCT07007767"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["sintilimab","bevacizumab","decitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07007767","phase":"2","setting":"An Open-label, Single-arm, Exploratory Study of Sintilimab in Combination With Bevacizumab and Decitabine for the Treatment of Advanced pMMR/MSS Colorectal Cancer in Third-line or Later Settings","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","enrolled":32,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07007767/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}